ERBB2 and breast carcinoma: Of the patients with HER2-positive breast cancer (N = 14), all received taxane and HER2-targeted therapy (e.g., trastuzumab alone, trastuzumab and pertuzumab) based regimens; ten (71%) received additional anthracycline and one (7%) received additional platinum agent.